Page 57 - Amgen News Today

My top 10 things to watch Friday, May 3 The Dow , the S & P 500 and the Nasdaq set to surge at Friday's open, moving a leg higher after data showing much…

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

A survey of North American equities heading in both directions

Things a looking well for the three Wall Street indices this morning. Investors welcome good news for the economy , and bad news for the economy .... -May 03, 2024 at 09:08 am EDT - MarketScreener

Goldman Sachs said Amgen's experimental GLP-1 drug could have peak sales of $5 billion, or 5% of the estimated $100 billion weight loss drug market.

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Wall Streets main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen also...

Amgen's potential weight loss drug is heading to a larger phase 3 trial

About 5000 leaders in health economics and outcomes research will gather for the 2024 meeting, which has the theme, "HEOR: A Transformative Force for Whole Health.”

Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.